Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

Together Trial, NCT04727424, TOGETHER, NCT04727424, Nov 2023
Famotidine for COVID-19
29th treatment shown to reduce risk in October 2021, now with p = 0.00028 from 30 studies, recognized in 2 countries.
Lower risk for mortality, hospitalization, recovery, and viral clearance.
No treatment is 100% effective. Protocols combine treatments.
6,300+ studies for 210+ treatments. c19early.org
Meta Analysis
528 patient famotidine early treatment RCT with results not reported over 2 years after completion.
Important missing comments or errors? Let us know.
Together Trial et al., 1 Nov 2023, Double Blind Randomized Controlled Trial, placebo-controlled, trial NCT04727424 (history) (TOGETHER). Contact: administrador@cardresearch.org, duduaugusto1@yahoo.com.br.
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0